New Zealand markets close in 1 hour 41 minutes
  • NZX 50

    11,797.72
    +45.63 (+0.39%)
     
  • NZD/USD

    0.6393
    -0.0010 (-0.15%)
     
  • NZD/EUR

    0.6213
    +0.0005 (+0.07%)
     
  • ALL ORDS

    7,303.20
    +64.50 (+0.89%)
     
  • ASX 200

    7,049.30
    +56.60 (+0.81%)
     
  • OIL

    91.82
    -0.11 (-0.12%)
     
  • GOLD

    1,800.50
    -13.20 (-0.73%)
     
  • NASDAQ

    13,378.32
    +370.16 (+2.85%)
     
  • FTSE

    7,507.11
    +18.96 (+0.25%)
     
  • Dow Jones

    33,309.51
    +535.11 (+1.63%)
     
  • DAX

    13,700.93
    +165.96 (+1.23%)
     
  • Hang Seng

    19,852.79
    +241.95 (+1.23%)
     
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • NZD/JPY

    85.1110
    +0.1100 (+0.13%)
     

DISCLOSURE OF LARGE SHAREHOLDING – AQUA-SPARK

·1-min read
Hofseth Biocare ASA
Hofseth Biocare ASA

Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the "Company") on 3 July 2022 regarding completion of a private placement of new shares (the "Private Placement"). In the Private Placement, the Company will issue a total of 35,490,000 new shares.

Aqua-Spark Coöperatieve U.A. applied for and was allocated 10,350,000 shares in the Private Placement at a price per share of NOK 4.  After the issuance of the new shares in the Private Placement, the shareholding of Aqua-Spark will be more than 5% of the Company's share capital.

Following the Private Placement, Aqua-Spark will hold 22,450,000 shares in the Company, corresponding to 5.71% of the shares and votes outstanding after completion of the Private Placement.

This information is subject to the disclosure requirements pursuant to Sections 4-2 and 5-12 of the Norwegian Securities Trading Act.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting